Selected Publications
Tsuchida CA, Brandes N, Bueno R, Trinidad M, Mazumder T, Yu B, Hwang B, Chang C, Liu J, Sun Y, Hopkins CR, Parker KR, Qi Y, Hofman L, Satpathy AT, Stadtmauer EA, Cate JHD, Eyquem J, Fraietta JA, June CH, Chang HY, Ye CJ, Doudna JA.: Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells Cell 186 (21): 4567-4582,2023.
Malek E, Kort J, Metheny L, Fu P, Hari P, Li G, Efebera Y, Callander N, Qazilbash M, Giralt S, Krishnan A, Stadtmauer E, Lazarus H.: Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial Res Sq : 2023.
Bixby TJ, Brittle CJ, Mangan PA, Stadtmauer EA, Kallenbach LR.: Patient Perceptions of CAR-T Therapy in the USA: Findings from In-Depth Interviews Oncol Ther : 2023.
Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW.: Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia Am J Hematol 98 (8): 2023.
Chippendale L, Freyer CW, Carulli A, Babushok DV, Frey NV, Gill SI, Hexner EO, Luger SM, Martin ME, Porter DL, Stadtmauer EA, Loren AW.: One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant J Oncol Pharm Pract : 2023.
Mohan M, Janz S, Brazauskas R, Dwinell MB, Teng BQ, Yun G, Dong J, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, D'Souza A.: Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy Bone Marrow Transplant 58 (8): 2023.
Landsburg DJ, Nasta SD, Svoboda J, Gerson JN, Schuster SJ, Barta SK, Chong EA, Difilippo H, Weber E, Cunningham K, Catania C, Garfall AL, Stadtmauer EA, Frey NV, Porter DL.: Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells Transplant Cell Ther 29 (8): 2023.
Hoeynck BW, Cohen AD, Stadtmauer EA, Susanibar-Adaniya SP, Vogl DT, Waxman AJ, Bardsley M, Le S, LaMaestra L, Garfall AL.: Progressive multifocal leukoencephalopathy in multiple myeloma Eur J Haematol : 2023.
Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA.: Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy Blood Cancer Discov 4 (2): 118-133,2023.
D'Souza A, Brazauskas R, Teng BQ, Yun G, Uttley H, Dong J, Dwinell MB, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, Janz S.: DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma Bone Marrow Transplant : 2023.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-171
3400 Civic Center Blvd
Philadelphia,
PA
19104
Phone: 215-662-7910
Patient appointments: 800-789-7366